reading 503B threads from 2024 and half of it aged badly
reading 503B threads from 2024 and half of it aged badly. I have gone back and forth on this for months.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
do not assume the concentration matches the branded product
What did the intake actually ask you?
a telehealth intake that asks nothing has told you what it is
salt forms are the recurring argument and the answer is boring
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Did they name the facility?
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
Correction: patient-specific refers to the prescription, not to a bespoke formulation.
Agreed — and the follow-up question is what the beyond-use date is based on.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
the pharmacy and the prescriber are two separate questions
shortage status changes and the whole arrangement changes with it
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
compounded is not generic, there is no equivalence claim
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
- 1A 503A pharmacy compounds for an identified patient against a prescription.…11 comments in this branch · started by u/santiago_rasmussen
- 2Compounded preparations are not approved products and carry no…10 comments in this branch · started by u/sofia_nascimento